Anti-Mouse CD96 – Purified in vivo PLATINUM™ Functional Grade

Clone 3.3 is a monoclonal antibody targeting mouse CD96, and its most common in vivo applications in mice include functional studies of immune modulation, particularly focusing on natural killer (NK) cells and T cells.

Essential applications include:

• Immune checkpoint studies: Clone 3.3 is commonly used to investigate the role of CD96 as an immune checkpoint receptor, especially regarding its inhibitory effects on NK cell activity. By blocking CD96 in vivo, researchers can assess changes in immune surveillance and anti-tumor responses.

• Tumor immunology: The antibody is employed in models of cancer to determine whether CD96 blockade can enhance NK cell-mediated tumor rejection or modulate T cell responses within the tumor microenvironment. This is based on the role of CD96 in controlling cytotoxicity and cytokine production by immune cells.

• Adoptive transfer and functional studies: It is used in combination with tumor challenge or adoptive cell transfer experiments to delineate how targeting CD96 alters the activation, migration, and effector functions of hematopoietic cells, particularly within solid tumors or after specific immune challenges.

• In vivo depletion or blockade: Clone 3.3 is administered in vivo to achieve functional blockade of CD96, not for cell depletion, but to directly interfere with receptor-ligand interactions, allowing researchers to study immune regulation mechanisms, including possible synergy or antagonism with other immune checkpoints.

Biological context:

• CD96 (Tactile) is predominantly expressed on T cells and NK cells, making clone 3.3 a specific tool for dissecting their roles in immune homeostasis and disease models, including infection and cancer.

Summary Table: Common In Vivo Applications of Clone 3.3

All sources agree on the main experimental uses but may differ on model specifics; suppliers and research summaries are most authoritative for antibody applications.

Commonly used antibodies or proteins studied alongside "3.3"—assuming you are referring to 14-3-3 proteins (based on usage in molecular and cell biology literature)—include targets that are known 14-3-3 binding partners, regulatory kinases, or signaling intermediates.

Key co-analyzed proteins/antibodies with 14-3-3 include:

• Phosphorylated client proteins: Many studies assess the interaction of 14-3-3 with phosphorylated forms of client proteins such as CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) and LRRK2 (Leucine-rich repeat kinase 2) for motif-binding analysis.
• Raf-1 kinase: A classic binding partner. 14-3-3 forms complexes with phosphorylated Raf-1, which can be assayed using antibodies against Raf-1 or phospho-specific Raf-1 antibodies.
• Gab2 (Grb2-associated binder 2): Especially in oncology research, Gab2 and its phosphorylated forms are tested in conjunction with 14-3-3, often using anti-Gab2 (total and phospho-specific) antibodies.
• Tau: In neuroscience, 14-3-3 interaction with phosphorylated tau is commonly analyzed using anti-14-3-3 and anti-phospho-tau antibodies.
• TASK3 channel: Particularly when studying motif III interactions, as FC-THF and related compounds can alter 14-3-3’s interaction with this potassium channel.

Experimental methods often involve:

• Immunoprecipitation with anti-14-3-3 and co-staining with antibodies against suspected partner proteins (e.g., phospho-specific antibodies for signaling kinases or channels).
• Functional assays using small molecule modulators and quantified by immunoblots with antibodies against 14-3-3, its isoforms, and client proteins.

Other antibodies/proteins sometimes included:

• GSK3 (Glycogen synthase kinase 3)
• AKT kinase
• BAD and FOXO (apoptosis and transcription factors)
• p53 or CDC25 (cell cycle regulators)
• Isoform-specific antibodies against various 14-3-3 family members (e.g., β, γ, ζ, δ, ε, η, σ, τ).

Alternative 3.3 usage: If you meant antibody isotype IgG3.3 or a different target, please specify, as these are not as universally standardized and co-targets would depend on context.

Summary Table: Proteins/Antibodies Commonly Used with 14-3-3 in Literature

If your context is different (e.g., a specific antibody clone "3.3"), please clarify, but most published data on "3.3" refers to the 14-3-3 protein family.

No search result directly addresses "clone 3.3" citations in the context of code, biology, medicine, or any specific scientific field. The last three search results mention the word "clone," but none provide information about "clone 3.3," nor do they summarize findings from citations of such a clone in the literature.

Your query could refer to a specific software tool, cell line, protein, gene, or another scientific entity—but without clarification or relevant results, it is not possible to summarize key findings from "clone 3.3" citations in the scientific literature based on the provided sources. If you have a specific scientific context or more details about "clone 3.3," please clarify so I can give a more targeted and accurate answer.

Dosing regimens for clone 3.3 (an anti-mouse CD96 monoclonal antibody) vary depending on the mouse model used, experimental goals, and desired immunological outcomes. The specific dose, frequency, and route of administration may be adjusted for differences in mouse strain, disease model, or the intended effect such as cell depletion versus immunomodulation.

• Dose per Mouse: Reported doses of clone 3.3 often range in the literature from about 200 μg to as high as 500 μg per mouse, depending on the degree of immune intervention required and mouse strain sensitivity.
• Frequency and Duration: Typical regimens involve administration every 2–3 days (for acute interventions) or weekly for longer-term immunomodulation. The number of doses can further vary with the experimental timeline (for example, repeated for 2–4 weeks in chronic studies).
• Route of Administration: Clone 3.3 is generally delivered via intraperitoneal (IP) injection for systemic effects, but may also use intravenous (IV) or local routes for specific tissue targeting if required by the experimental design. Variations in absorption and biodistribution can affect efficacy.

Key factors influencing dosing across mouse models:

• Mouse strain: Sensitivity, immunological baseline, and metabolism can affect the optimal dose. For instance, C57BL/6 versus BALB/c mice may require dosing adjustment based on genetic background or tumor model.
• Disease model: Tumor-bearing mice might receive more frequent dosing compared to infectious disease or autoimmunity models.
• Goal of treatment: Cell depletion protocols (e.g., for depleting NK or T cells) may use higher or more frequent doses than protocols aimed at blocking a receptor.

Summary Table: Typical Dosing Regimen Properties for Clone 3.3

• Dosing can deviate from these standards based on specific experiment needs, pilot studies, or published protocols for similar clones (see anti-mouse CD96 and other immune cell depleting antibodies).
• Always adjust regimens based on published guidance, preliminary titrations, and the specifics of the disease/tissue model.

Exact clone 3.3 regimens should be validated for each new experimental setting, taking into account mouse genetics, disease burden, and desired immune impact. For additional details, refer to peer-reviewed antibody dosing guides and product-specific recommendations.